Abstract:Louis Chhor, 1, 2 Stefan Saggese, 2 Garun S Hamilton, 1, 3 Martin Ian MacDonald 1 1 Monash Lung, Sleep, Allergy & Immunology, Monash Health, Melbourne, Victoria, Australia; 2 Department of General Medicine, Monash Health, Melbourne, Victoria, Australia; 3 School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia Correspondence: Louis Chhor, Department of General Medicine, Dandenong Hospital, 135 David St, Dandenong, VIC, 3175, Australia, Tel +61 3 9544 1000, Email Objective: To compare clinical characteristics and outcomes of hospitalized acute exacerbations of COPD (AECOPD)s secondary to SARS-CoV-2 versus other respiratory viruses amongst a highly vaccinated population in the Omicron era. Design: Retrospective cohort study; analysis of hospital medical records and linked pathology and radiology reports. Setting: Tertiary health network in Victoria, Australia; January 2022–August 2022. Main Outcome Measures: Key clinical information including comorbidities, vaccination status, treatments administered and outcomes such as hospital length of stay, ICU admission, non-invasive ventilation usage and inpatient mortality. Results: One hundred ninety-nine viral AECOPDs - 125 SARS-CoV-2 and 74 other viruses were identified. Of the SARS-CoV-2 group. 13.6% were unvaccinated, 17.6% partially and 68.0% fully vaccinated. The SARS-CoV-2 group were older (77.2 vs 68.9, p < 0.00001) with more comorbidities (1[1– 2] vs 1[0– 2], p = 0.008) and lower candidacy for full resuscitation (25.6% vs 56.8%, p < 0.0001). Mortality tended to be higher among SARS-CoV2 admission (9.6% v 2.7%, p = 0.066) but rates of ICU admission (10.4% v 13.5%, p = 0.507), length of hospitalisation (5[3– 8] vs 5[3– 9], p = 0.9) and readmission within 30 days (25% vs 33.3%, p = 0.184) were similar. Conclusion: In a highly vaccinated population in the Omicron era, COPD patients requiring hospitalisation with SARS-CoV-2 are older with more comorbidities than those admitted with other respiratory viruses. Length of hospitalisation and ICU utilisation was similar. Inpatient mortality may be higher. Keywords: SARS-CoV2, coronavirus, COPD, viral exacerbations Patients with chronic obstructive pulmonary disease (COPD) are vulnerable to severe acute exacerbations (AECOPDs) when they contract respiratory viruses. 1 Exacerbations of COPD are cardinal events in the disease, associated with accelerated decline in lung function, reduced quality of life, hospitalization and mortality. 2–4 Viral infection appears to be responsible for up to 50% of AECOPDs. 5,6 The prognosis of virus-associated exacerbation appears different to other exacerbation etiotypes, with a slower recovery and prolonged hospitalization. 7,8 In general, studies examining hospitalized AECOPDs have considered all respiratory viruses as a generic grouping, with outcomes compared between "viral" and "non-viral" exacerbations or versus alternative broad etiologies such as bacterial or eosinophilic exacerbations. 9–11 Studies of individual viruses such as rhinovirus ("common cold"), influenza and Respiratory Syncytial Virus (RSV) have been performed, although there are very limited data to indicate whether specific respiratory viruses have different impacts as causes of severe AECOPDs. The relative impact of SARS-CoV-2 versus previously circulating respiratory viruses as a cause of severe AECOPD has been little studied. One prospective observational cohort study in the United Kingdom compared outcomes from AECOPDs secondary to SARS-CoV-2 versus groups with either alternative infections (bacterial or viral), or non-infective AECOPDs. 10 They reported higher 30-day mortality, longer hospital stays and more frequent requirement for positive pressure ventilatory support among the SARS-CoV-2 group. Much of this data was collected during the early phases of the pandemic with circulating wild-type, alpha and delta strains. Since the onset of the COVID pandemic, widespread vaccination and development of effective therapeutics have been achieved, limiting applicability of early pandemic data to the current era. SARS-CoV-2 is now an endemic community respiratory virus, and it is therefore necessary to evaluate the clinical phenotype of AECOPD secondary to SARS-CoV-2 contextualized alongside other commonly circulating respiratory viruses. We hypothesized that sub-populations of COPD patients may be more vulnerable when hospitalized with AECOPD due to SARS-CoV-2 compared to other respiratory viruses, which may inform and guide clinical management, prevention strategies and prognosis. We therefore analyzed hospi -Abstract Truncated-

Impact of baseline SARS-CoV-2 load in plasma and upper airways on the incidence of acute extrapulmonary complications of COVID-19: a multicentric, prospective, cohort study

High anal swab viral load predisposes adverse clinical outcomes in severe COVID-19 patients

Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge

Key to successful treatment of COVID 19: accurate identification of severe risks and early intervention of disease progression

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19

Estimated plasma volume status in COVID-19 patients and its relation to comorbidities and clinical outcomes

SARS-CoV-2 viremia but not respiratory viral load is associated with respiratory complications in patients with severe COVID-19

Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study

Excess Burden of Respiratory and Abdominal Conditions Following COVID-19 Infections During the Ancestral and Delta Variant Periods in the United States: an EHR-based Cohort Study from the RECOVER Program.

SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

Early Treatment, Inflammation and Post-COVID Conditions

Early biological markers of post-acute sequelae of SARS-CoV-2 infection

Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC)

Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals

Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses

Extracellular vesicles containing SARS‐CoV‐2 proteins are associated with multi‐organ dysfunction and worse outcomes in patients with severe COVID‐19

Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection

Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19